Glycitein (Isoflavone · Antioxidant · Minor Soy Phytoestrogen)

Compound	Glycitein (6-Methoxydaidzein; 7-Hydroxy-6-methoxy-3-(4-hydroxyphenyl)-4H-chromen-4-one)
Chemical class	Polyphenol — Isoflavone (6-O-methylated daidzein; unique A-ring methoxylation — only major soy isoflavone with A-ring modification)
CAS	40957-83-3
Primary source	Glycine max (soybean — present at 5–10% of total soy isoflavone content)
Key applications	Antioxidant; phytoestrogenic (minor); anti-inflammatory; skin brightening research
Claim strength	Moderate
Typical form	Soy Isoflavones 80% extract (glycitein as 5-10% of the isoflavone complex); not separately standardised commercially
Buy from Herbuno	Soy Isoflavones 80% Powder (Soy Extract) | Standardized Glycine max → Soy Isoflavones 40% Powder (Soy Extract) | Standardized Glycine max →

Name origin: Glycitein is named after Glycine max — the soybean — from which it is exclusively sourced at commercially meaningful concentrations. Unlike genistein (5,7,4′-trihydroxyisoflavone) and daidzein (7,4′-dihydroxyisoflavone), glycitein carries a methoxy group at the unusual C-6 position of the A-ring, making it the only major soy isoflavone with A-ring O-methylation. Traditional use: Glycitein has no independent traditional medicinal use — it is a minor constituent of soy foods, present at approximately 5–10% of total soy isoflavone content compared to genistein (~60%) and daidzein (~30%). Traditional soy food consumption (miso, natto, tofu, tempeh) delivers glycitein in proportion to its natural abundance. Fermented soy preparations (natto, tempeh) yield higher aglycone forms of all three isoflavones including glycitein. Research trajectory: Glycitein's unique 6-methoxy A-ring gives it distinct biological properties compared to genistein and daidzein — altered cell membrane penetration, different cytochrome P450 metabolism, and distinct antioxidant radical-scavenging geometry. Research has identified glycitein in melanocyte biology (tyrosinase modulation), with potential skin-brightening applications distinct from genistein and daidzein's primarily systemic phytoestrogenic effects. Commercial source: Glycitein is co-delivered in Soy Isoflavones 80% Powder from Herbuno at approximately 5–10% of the total isoflavone fraction — not separately standardised but confirmed present by HPLC.

---

Evidence for Glycitein Applications

Antioxidant activity: Glycitein's 6-methoxy A-ring combined with the 4′-hydroxyl B-ring creates a distinct radical-scavenging geometry. DPPH and ABTS scavenging activity is comparable to daidzein. Unique to glycitein is its higher lipophilicity versus genistein and daidzein (the A-ring methoxy group increases logP), potentially improving membrane penetration for intracellular antioxidant activity. Claim strength: Moderate.

Phytoestrogenic activity: Glycitein binds ERα and ERβ with affinity substantially lower than genistein but comparable to or slightly above daidzein. ERβ selectivity is maintained. In menopausal symptom RCTs using total soy isoflavone preparations, glycitein contributes to the overall phytoestrogenic effect proportionally to its ~5–10% representation in the isoflavone complex. Isolated glycitein clinical studies do not exist. Claim strength: Moderate (mixture); Emerging (isolated).

Skin brightening / tyrosinase modulation: Glycitein has been identified as a tyrosinase inhibitor in melanocyte cell models — reducing melanin biosynthesis at micromolar concentrations. The 6-methoxy group distinguishes glycitein's tyrosinase binding from genistein and daidzein, giving it differentiated depigmentation activity relevant to topical cosmetic applications. Claim strength: Emerging.

Anti-inflammatory: NF-κB and COX-2 inhibition at micromolar concentrations are documented for glycitein, consistent with the soy isoflavone class. TNF-α reduction in macrophage activation models aligns with genistein's profile. Claim strength: Moderate.

---

Dosage & Formulator Specification

No isolated glycitein human dosing data exist. In standard soy isoflavone supplementation (40–80 mg/day total isoflavones), glycitein is delivered at approximately 2–8 mg/day — a minor contributor to the total phytoestrogenic effect. Soy Isoflavones 80% from Herbuno delivers glycitein at approximately 4–8% of the isoflavone fraction alongside genistein (~60%) and daidzein (~30%).

Glycitein's higher lipophilicity versus genistein and daidzein suggests it may penetrate biological membranes more readily, reaching intracellular antioxidant and enzyme inhibition targets at lower plasma concentrations. For formulators targeting glycitein specifically (e.g., for skin brightening applications), concentrated glycitein isolate from soy fractionation is available from specialty isoflavone suppliers; standard soy extract delivers only trace glycitein concentrations insufficient for isolated pharmacological activity.

Stability of glycitein in formulations is good — the 6-methoxy group reduces susceptibility to oxidation at the A-ring compared to free hydroxyl-bearing isoflavones. Compatible with standard soy isoflavone formulation vehicles (capsule, tablet, softgel); aqueous solutions require pH 4–7 and nitrogen protection.

Safety considerations for glycitein are those of the soy isoflavone class broadly: ER-positive condition caution; thyroid considerations at high doses; avoid in pregnancy. No glycitein-specific safety concerns are identified.

---

Frequently Asked Questions — Glycitein

What makes glycitein structurally unique among soy isoflavones?
Glycitein is the only major soy isoflavone with an A-ring O-methylation — specifically at C-6, a position not modified in genistein or daidzein. This 6-methoxy group increases lipophilicity, alters the electronic distribution across the A-ring affecting radical scavenging geometry, and modifies the molecule's fit in tyrosinase and CYP enzyme active sites. The 6-methoxy A-ring pattern is unusual among isoflavones broadly and shared only with a small number of plant-specific methylated isoflavones.

Is glycitein present in all soy isoflavone supplements?
Yes — it is a natural constituent of soybean seeds and therefore present in all authentic soy isoflavone preparations. However, at only 5–10% of total isoflavone content, it may not be separately specified in commercial CoAs that report genistein and daidzein as the primary markers. Full HPLC isoflavone profiling (distinguishing genistein, daidzein, glycitein, and their glycoside forms — genistin, daidzin, glycitin) is the quality standard for research-grade soy isoflavone characterisation.

Can glycitein contribute to skin brightening in topical formulations?
Glycitein's tyrosinase inhibition in cell models suggests potential utility in topical depigmentation formulations — a different application from the primarily oral phytoestrogenic use of genistein and daidzein. Topical soy extract formulations used in cosmetic skin brightening already deliver glycitein as a minor constituent; isolated glycitein at higher concentrations may offer differentiated tyrosinase inhibition. This application area has not been validated in clinical trials and represents an emerging opportunity.

How is glycitein absorbed compared to genistein and daidzein?
Glycitein follows the same gut absorption pathway as other soy isoflavones: the primary dietary form is glycitin (glycitein-7-O-glucoside), which requires gut beta-glucosidase hydrolysis to release glycitein aglycone for absorption. Glycitein aglycone's higher lipophilicity may result in marginally better passive absorption than daidzein once the glucoside is cleaved. Colonic microbial transformation of unabsorbed glycitein has not been characterised to the same extent as genistein and daidzein metabolism.

Related compounds: Genistein, Daidzein, Daidzin, Formononetin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery